>
Organization
Alexion Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Alexion Pharmaceuticals, Inc.

... SAN FRANCISCO—In 2019, Alexion is looking to pivot from an ultrarare-disease company to a rare-disease company—andit ...
... drug Aimovig. But pricing hasn't been much on the agenda, except at Alexion, which says it needs an entirely new strategy. What has? Drug launches—Lilly's ...
... Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results ...
... recently, Dr. Ryder served as Senior Vice President, Chief Development Officer at Alexion Pharmaceuticals, where he led the global development, registration, and approval of new ...
... age. Most recently, Julie was Executive Vice President, Global Operations for Alexion Pharmaceuticals Inc.- As part of these operational changes announced today, Alan Kerr, Senior ...
... Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 37th Annual ...
... nocturnal hemoglobinuriaPeak sales estimate:$5 billion by 2022 (for Soliris and Ultomiris combined)Approved:Dec. 21Company:Alexion The scoop:Alexion is out with a new-and-improved version of lead drug Soliris, ...
... Alexion was expecting a decision on its Soliris successor by February, but thanks ...
... Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Goldman Sachs 11th ...
... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) ...
Subscribe now for full coverage on Alexion Pharmaceuticals, Inc.
Start My Free Trial